We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Beneficial Mutation Dissociates Obesity from Diabetes

By LabMedica International staff writers
Posted on 23 Dec 2009
A potentially beneficial mutation has been identified that seems to dissociate obesity from the danger of developing type II diabetes.

Although some 20 to 30% of obese individuals fail to progress to diabetes, and while some nonobese individuals do develop the disease, the current report is perhaps the first to link these observation to the action of a specific gene.

Investigators at the Boston University School of Medicine (MA, USA) discovered a mutation of the Brd2 (Bromodomain-containing protein 2) gene in a population of laboratory mice. More...
These animals became severely obese but did not go on to develop type II diabetes. Specifically, reduced function of the Brd2 gene enhanced glucose tolerance; elevated adiponectin; increased the weight of brown adipose tissue; increased heat production and expression of mitochondrial uncoupling proteins in brown adipose tissue; reduced macrophage infiltration in white adipose tissue; and lowered blood glucose, leading to an improved metabolic profile and avoiding eventual type II diabetes.

These findings were published in the November 2, 2009, online edition of The Biochemical Journal (BJ) where the authors also noted that Brd2 was highly expressed in pancreatic beta cells, where it normally inhibits beta-cell mitosis and insulin transcription.

Senior author Dr. Gerald Denis, assistant professor of pharmacology and medicine at the Boston University School of Medicine, said, "Studies have shown that these individuals [obese but free of type II diabetes] have a reduced "inflammatory profile". Inflammation caused by normal immune cells called macrophages leads to insulin resistance and type II diabetes - this inflammation is typically seen in connection with obesity but it is the inflammation that is a trigger for diabetes, not the obesity itself. The mechanisms that explain this protection from diabetes are not well understood. Much like these protected obese humans, the Brd2-deficient mice have reduced inflammation of fat and never develop failure of the beta cells in the pancreas that is associated with type II diabetes."

"The strong influence of Brd2 levels on insulin production and action suggest that Brd2 is likely to be a promising target for diabetes treatment, but also imply that overactive Brd2 might cause diabetes," said Dr. Denis. "The ways in which Brd2 affects the immune system may also play a part in type I diabetes; further studies to determine this are needed."

Related Links:
Boston University School of Medicine



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.